TRIZIVIR

This brand name is authorized in Austria, Australia, Estonia, Spain, Finland, France, Hong Kong, Ireland, Lithuania, Netherlands, Poland, Romania, United Kingdom, United States

Active ingredients

The drug TRIZIVIR contains a combination of these active pharmaceutical ingredients (APIs):

1 Abacavir
UNII J220T4J9Q2 - ABACAVIR SULFATE

Abacavir is a NRTI. It is a potent selective inhibitor of HIV-1 and HIV-2. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). In vitro studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle.

Read about Abacavir
2 Lamivudine
UNII 2T8Q726O95 - LAMIVUDINE

Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription.

Read about Lamivudine
3 Zidovudine
UNII 4B9XT59T7S - ZIDOVUDINE

Zidovudine is an antiviral agent which is highly active in vitro against retroviruses including the Human Immunodeficiency Virus (HIV).

Read about Zidovudine

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
TRIZIVIR Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J05AR04 Zidovudine, lamivudine and abacavir J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 10305J
Country: EE Ravimiamet Identifier(s): 1110980
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 100156004
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 435748
Country: FR Base de données publique des médicaments Identifier(s): 64976070
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 44192
Country: HK Department of Health Drug Office Identifier(s): 49277
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1007906, 1031458, 1055422, 1056594
Country: NL Z-Index G-Standaard, PRK Identifier(s): 136026
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100110487
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W65016001, W65016002
Country: US FDA, National Drug Code Identifier(s): 49702-217

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.